Literature DB >> 7440567

Glucagon amino groups. Evaluation of modifications leading to antagonism and agonism.

M D Bregman, D Trivedi, V J Hruby.   

Abstract

Using native glucagon and [12-homoarginine]glucagon (analogue A), prepared in high yield and purity by new procedures, we have synthesized the following glucagon analogues by semisynthetic methods: [1-deshistidine][12-homoarginine]glucagon (analogue B); N alpha-carbamoylglucagon (analogue C); N alpha, N epsilon-dicarbamoylglucagon (analogue D); [1-N alpha-carbamoylhistidine, 12-N epsilon-trinitrophenyllsyine]glucagon (analogue II); [1-deshistidine] [2-N alpha-trinitrophenylserine, 12-homoarginine]glucagon (analogue III); and [1-N alpha-trinitrophenylhistidine, 12-homoarginine]glucagon (analogue IV). The introduction of hydrophylic groups at the alpha- and epsilon-amino positions of glucagon results in a reduction in potency. The alpha-position is also involved in biological activity. Carbamylation of the alpha-position results in a partial agonist (analogues C and D). The introduction of hydrophobic groups and the neutralization of the positive charge at the alpha- and epsilon-amino positions result in glucagon antagonists (analogues II, III, and IV). [1-N alpha-Trinitrophenylhistidine, 12-homoarginine]glucagon (analogue IV) is the most potent inhibitor tested. Based on its competitive inhibitory action, this analogue appears to have about one-third the affinity of glucagon for the receptor site. These modifications at the epsilon-amino position cause an increase in the secondary structure of the peptide (as shown by circular dichroism studies) which may be related to their biological activities.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7440567

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Resensitization of hepatocyte glucagon-stimulated adenylate cyclase can be inhibited when cyclic AMP phosphodiesterase inhibitors are used to elevate intracellular cyclic AMP concentrations to supraphysiological values.

Authors:  G J Murphy; M D Houslay
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

2.  Hormonal regulation of Gi2 alpha-subunit phosphorylation in intact hepatocytes.

Authors:  M Bushfield; G J Murphy; B E Lavan; P J Parker; V J Hruby; G Milligan; M D Houslay
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

3.  Relationships among several different non-homologous polypeptide hormones.

Authors:  R M Epand
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

4.  Synthetic peptide antagonists of glucagon.

Authors:  C G Unson; D Andreu; E M Gurzenda; R B Merrifield
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

5.  The rapid desensitization of glucagon-stimulated adenylate cyclase is a cyclic AMP-independent process that can be mimicked by hormones which stimulate inositol phospholipid metabolism.

Authors:  G J Murphy; V J Hruby; D Trivedi; M J Wakelam; M D Houslay
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

6.  Insulin and glucagon attenuate the ability of cholera toxin to activate adenylate cyclase in intact hepatocytes.

Authors:  F J Irvine; M D Houslay
Journal:  Biochem J       Date:  1988-04-15       Impact factor: 3.857

Review 7.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

Review 8.  Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.

Authors:  V J Hruby
Journal:  Mol Cell Biochem       Date:  1982-04-16       Impact factor: 3.396

9.  Hepatic glucagon metabolism. Correlation of hormone processing by isolated canine hepatocytes with glucagon metabolism in man and in the dog.

Authors:  W A Hagopian; H S Tager
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.